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Background: More than 50% of cancer patients are recommended to receive radiotherapy. Recommendations are
based mainly on clinical and pathological factors and not intrinsic tumour radio-sensitivity. Use of radiotherapy
according to predictive markers would potentially reduce costly over-treatment, and improve the treatment
risk-benefit ratio and cancer outcomes. Tumour expression of the 26S proteasome has been reported to predict
radiotherapy response: low expression was associated with higher rates of local recurrence after radiotherapy,
suggesting that low proteasome expression and activity was associated with radio-resistance. However, this
conclusion is at odds with the emerging use of proteasome inhibitors as radio-sensitizers. Our aim was to further
analyse the relevance of 26S proteasome expression, focussing specifically on the PSMD9 subunit, in the largest
clinical cohort to date, and to investigate the functional role of PSMD9 in radio-sensitivity in breast cancer cell lines.
Methods: We examined expression of PSMD9 using immunohistochemistry in a cohort of 157 breast cancer
patients, including 32 cases (20.4%) that subsequently developed local recurrences. The value of expression as a
prognostic or radiotherapy predictive marker was tested using Kaplan-Meier and Cox regression analyses. PSMD9
function was examined in breast cancer cell lines MCF7 and MDA-MB-231 using siRNA knock-downs and colony
forming assays after irradiation.
Results: Low tumour PSMD9 expression was significantly associated with a reduced incidence of local recurrence in
patients receiving adjuvant radiotherapy (univariate log rank p = 0.02; multivariate regression p = 0.009), but not in
those treated without radiotherapy, suggesting that low PSMD9 expression was associated with relative tumour
radio-sensitivity. In support of this, reduction of PSMD9 expression using siRNA in breast cancer cell lines in vitro
sensitized cells to radiotherapy.
Conclusions: We conclude that PSMD9 expression may predict radiotherapy benefit, with low expression indicative
of relative radio-sensitivity, the opposite of previous reports relating to 26S proteasome expression. Our conclusion
is compatible with use of proteasome inhibitors as radio-sensitizers, and highlights PSMD9 as a potential target for
radio-sensitizing drugs.
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Radiotherapy (RT) is a critical component of loco-
regional cancer management and is used in over 50% of
cancer patients [1]. RT treatment decisions are based on
clinical factors, morphology-based pathological indica-
tors, the extent of surgery, and/or clinician and patient
choice rather than tumour molecular profiles predictive
of recurrence and likely RT sensitivity. As a result, some
patients are treated with RT although their tumours are
relatively resistant, and these patients are unlikely to de-
rive therapeutic benefit. This represents over-treatment
in terms of resources and contributes to treatment-
induced morbidity [2]. Biomarkers indicative of likely
RT response would allow therapy to be assigned more
effectively [3] yet development of such markers has pro-
gressed little [4]. Several potential markers can be identi-
fied from the literature: for example, in breast cancers
expression levels of HJURP mRNA can predict patient
survival after RT [5] and high cytoplasmic expression of
peroxiredoxin-I correlated with increased local recur-
rences after RT [6]. However, in most cases predictive and
prognostic information from potential markers has not
been separated and markers have typically not been vali-
dated in further studies. Consequently, predictive markers
for RT are not close to entering clinical practice [3].
One potential predictive marker of interest is the 26S
proteasome; this has been associated with patient out-
come after RT in two independent studies and, in
addition, is itself a target for cancer therapeutics. The
26S proteasome is a 2.6 MDa complex of at least 47
polypeptide subunits [7], and the complex is responsible
for the degradation up to 80% of cellular proteins [8].
Work with respect to RT response has focused on ex-
pression of the p32 subunit of the 20S core particle of
the proteasome. Unfortunately, the gene encoding this
subunit and therefore its exact molecular role remain
unclear. Further confusion concerning the antibody used
and its target has derived from the target being referred
to as “the 26S proteasome”, as opposed to as the individ-
ual specific subunit, or in some sources as a different
proteasomal subunit, p27. Low p32 expression in tu-
mours was significantly associated with an increase in
local recurrence in laryngeal cancer patients who were
treated with single modality RT with curative intent [9].
Similarly, low expression of p32 was significantly associ-
ated with increased local recurrences in a small cohort
of breast cancer patients who were treated with adjuvant
RT [10]. Thus, it was inferred that low 26S proteasome
function was associated with relative resistance to RT.
However, this correlation is potentially at odds with the
apparent function of proteasome inhibitors as cancer
therapeutics. Other studies have shown that inhibition of
26S proteasome function can render tumour cells par-
ticularly sensitive to DNA damaging agents includingionising radiation [11,12], and can reduce tumour cell
proliferation and induce apoptosis [13]. Accordingly, the
proteasome inhibitor Bortezomib (Velcade; Millenium
Pharmaceuticals) is now used in the treatment of some
haematological malignancies [14,15] and is undergoing
trials for use in other cancers, including solid tumours
[16]. The conflict is that intrinsically low 26S prote-
asome levels (or at least of the p32 subunit) appear to
correlate with RT resistance and therefore local recur-
rence [9,10], while reduction of 26S proteasome function
sensitizes tumour cells to RT and reduces cancer cell via-
bility. Our aim in this study was to analyse further the
value of the 26S proteasome as a predictive marker for
RT and a prognostic marker for local recurrence in
breast cancer using a cohort that is substantially larger
than any previous study. We focused on a different sub-
unit, PSMD9, which is an associated component of the
19S regulatory particle of the 26S proteasome [7]. This
was because we were able to validate the specificity of
an antibody against this subunit, and we were able to
use RNA interference to manipulate expression in vitro
since the encoding gene is known. We also aimed to
investigate in vitro whether the PSMD9 proteasomal
subunit may represent a more specific target for radio-
sensitizing therapies.
Results
PSMD9 expression predicts response to RT in breast
cancers
First, we selected and validated an antibody with the ap-
propriate specificity for a subunit of the 26S proteasome.
We were unable to demonstrate the specificity for p32
of the clone used in the previously published work
[9,10], therefore we selected a different antibody against
the PSMD9 subunit. We performed Western blot ana-
lyses to confirm that our antibody recognised a protein
of the appropriate size for PSMD9 (~25 kDa) in breast
cancer cell lines (Figure 1). Critically, the antibody
recognised only a single protein species of the correct
size demonstrating that it did not cross-react with other
proteins in breast epithelial cells and was therefore po-
tentially suitable for use in immunohistochemistry of
tissues.
Next, our aim was to examine whether PSMD9 ex-
pression in tumours was associated with response to RT.
We have taken local recurrences (LRs) after resection
surgery and adjuvant RT to be indicative of poor re-
sponses to RT. LRs of breast cancers are relatively un-
common, occurring in less than 7% of patients after 5
years [2], therefore it was not possible to use a sequen-
tial cohort of breast cancers to test the relationship be-
tween PSMD9 expression and LR without the cohort
being prohibitively large. We assembled a cohort of pri-
mary breast tumours that was selected to contain a
Figure 1 The anti-PSMD9 antibody used in this study recognises
only one protein, which is of ~25 kDa - the predicted size for
PSMD9, in breast cancer cell lines.
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(20.4%). Expression of PSMD9 was examined using im-
munohistochemistry in these 157 breast tumours, taking
into account the proportion of tumour cells staining posi-
tively, and their intensity using the Allred system [17].
Representative stained tissue samples are shown in
Figure 2A-C. PSMD9 staining was absent in most
cases (69.4%), while positive staining varied from weak
to strongly positive in differing proportions of cells
(Figure 2D). Clinico-pathological data for the patients
and tumours are described in Table 1. PSMD9 expres-
sion did not correlate significantly with patient age or
with tumour characteristics (grade, size, receptor sta-
tus, lymph node status; Additional file 1: Table S1).
PSMD9 expression was dichotomised in order to allow
Kaplan-Meier analyses of the influence of PSMD9 on
LR. Receiver operator curve analysis was performed in
order to select a cut off objectively that gives the best
balance between sensitivity and specificity for the end
point of LR, and therefore allows the strongest use of
these scoring data (Additional file 2: Figure S1). A cut
off of 1 was selected, thereby defining tumours with no
staining for PSMD9 as negative, and those with anystaining as positive. Kaplan-Meier analyses were per-
formed to study influences of PSMD9 expression on LR in
the entire cohort (Figure 3A). Positive expression of
PSMD9 was significantly associated with an increased LR
rate (p = 0.03), suggesting that PSMD9 provides prognos-
tic information. Moreover, when the cancer cohort was di-
vided into patients treated with RT (n = 110) and patients
treated without RT (n = 47) insights were gained into the
predictive value of PSMD9 for RT (Figure 3B and C). It
should be noted that type of surgical operation (wide local
excision vs mastectomy) and lymph node status were the
only significant clinico-pathological differences between
the groups treated with or without RT (Additional file 3:
Table S2); tumour size, grade or receptor expression did
not differ significantly. Lymph node positivity and surgery
type are used to select patients for RT, therefore these dif-
ferences were expected. Positive expression of PSMD9
was significantly associated with LR specifically in patients
who received RT (Figure 3B, p = 0.02), but not in those
who did not receive RT (Figure 3C, p = 0.75).
Multivariate regression analysis was performed to as-
sess whether the predictive value of PSMD9 was inde-
pendent of standard prognostic characteristics in the
cohort treated with RT. Variables included were tumour
size and grade, lymphovascular invasion, lymph node
status, and PSMD9 expression. Only PSMD9 expression
was significantly associated with LR in this analysis, with
positive expression increasing LR risk by a hazard ratio
of 2.9 (95% confidence intervals 1.3-6.4; p = 0.009), indi-
cating that PSMD9 gave predictive insights that were
unrelated to standard prognostic factors.
Knock-down of PSMD9 sensitises breast cancer cells to RT
In order to determine whether PSMD9 expression was
functionally associated with response to RT, we manipu-
lated PSMD expression using siRNA in breast cancer
cell lines and assessed sensitivity to RT in vitro. First,
MCF7 cells were transiently transfected with siRNAs
targeting PSMD9 or with a non-targeting control, and
PSMD9 expression was examined using Western blot-
ting (Figure 4A). Expression of PSMD9 was dramatic-
ally reduced by the targeted siRNAs. PSMD9 knock-
down had no significant influence on cell survival/
growth 48 h after transfection (Figure 4B) suggesting
PSMD9 expression has little influence on the short-
term survival of the bulk population of cells. Next, we
performed colony-forming assays with breast cancer
cell lines representative of both luminal A (MCF7) and
the basal (MDA-MB-231) subtypes after transfection
with PSMD9-targeting siRNA, or control, and after dif-
ferent doses of radiation from 0 to 10 Gy (Figure 4C).
Cells surviving irradiation and maintaining sustained
proliferative potential were quantified by counting indi-
vidual colonies. Knock-down of PSMD9 significantly
Figure 2 PSMD9 is variably expressed in breast cancers. A-C Representative staining patterns in individual tissue microarray cores. Cores
showing negative staining (A), and staining scored 3 (B) or 7 (C) are shown. D A histogram showing the distribution of immunohistochemistry
scores. Scores (x-axis) and numbers of cases assigned to each score (y-axis) are shown. Numbers and percentages of the cohort are given above
each bar.
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except MCF7 cells at 4 Gy and MDA-MB-231 at 8 Gy,
which did not reach statistical significance). The propor-
tion of cells surviving RT was reduced by up to 10-fold
after PSMD9 knock-down.
Conclusions
We show that low expression of the 26S proteasome
subunit PSMD9 was significantly associated with re-
duced incidence of LR in breast tumours after adjuvant
RT. Our results for PSMD9 are, in essence, opposite to
those of previous studies on the prognostic/predictive
value of the expression of the proteasomal subunit p32
in cancers, in which low p32 expression was found to as-
sociate with increased LR rates after RT [9,10]. Two fac-
tors are worthy of discussion with respect to this
apparent conflict. Firstly, and most obviously, the reports
focus on different subunits of the proteasome and it is
plausible that the two subunits have opposite correla-
tions with RT response. It remains unclear whether ex-
pression of either is representative of proteasomal
activity, as would be relevant when considering therapies
with proteasome inhibitors. Secondly, we have used a
cohort of cancer cases (n = 157) that is substantially
larger than those in the previous studies (n = 47 [9]
and n = 28 [10]) therefore our result may be more ro-
bust. A further key point related to this is that we are
the first to attempt to separate the predictive andprognostic aspects of expression of a proteasomal sub-
unit (Figure 3). The previous studies used cohorts
where all patients received RT [9,10] therefore it was
not possible to determine whether expression corre-
lated with outcome irrespective of treatment (prognos-
tic) or with RT response (predictive). In breast cancers,
we found PSMD9 expression to correlate with out-
come only in patients treated with RT (Figure 3B), in-
dicating that PSMD9 represents a RT predictive
marker rather than a simple prognostic marker for LR.
While statistically significant, this result is potentially
flawed by the low LR rate in patients who did not re-
ceive RT (Figure 3C). This flaw is unfortunately experi-
mentally intractable for breast cancer since only
patients at a low risk of LR are spared RT (for example,
those with negative lymph nodes after mastectomy)
therefore LRs are inevitably very uncommon in the no
RT group. A further difficulty that follows from this is
that the groups that receive and do not receive RT dif-
fer in terms of their lymph node status, although not
in other pathological parameters (Additional file 3:
Table S2).
The need for RT predictive markers has long been
highlighted [4]. It is well established that breast cancer
subtypes (as defined by estrogen receptor, progesterone
receptor, and her-2 expression) correlate with LR rates
[18,19], with the highest rates in the estrogen receptor
negative subtypes. There is evidence that these
Table 1 Clinico-pathological features of the breast cancer
cohort (n = 157)
Characteristic Category Number of
cases (%)
Age (years) Median: 59
Range: 31-93
Surgery Wide local excision 89 (56.7)
Mastectomy 68 (43.3)
Grade 1 29 (18.5)
2 73 (46.5)
3 55 (35.0)
Size (cm) <2 73 (46.5)
2-5 69 (43.9)
>5 15 (9.6)
Hormone receptors ER + 111 (70.7)
ER - 46 (29.2)
HER2 + 4 (2.5)
HER2 - 18 (11.5)
HER2 unknown 135 (86.0)
LN status (number positive nodes) 0 86 (54.8)
1-3 40 (25.5)
4+ 26 (16.6)
Unknown 5 (3.2)
Adjuvant therapy Chemotherapy 40 (25.5)
No chemotheray 117 (74.5)
Endocrine 115 (73.2)
No endocrine 29 (18.5)
Endocrine unknown 13 (8.3)
RT 110 (70.1)
No RT 47 (29.9)
Local recurrence Yes 32 (20.4)
No 125 (79.6)
Systemic recurrence Yes 49 (31.2)
No 108 (68.8)
Follow-up (months) Median: 96
Range: 9-220
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[20], although this is not well accepted enough to be
taken into account when stratifying patients for RT. We
do not find PSMD9 expression to correlate with estro-
gen receptor expression (Additional file 1: Table S1),
therefore we do not believe it to be involved with the
differential RT response between these groups; we can
not comment on the relationships between her-2,
PSMD9 and response, as her-2 data are lacking for our
cohort, which largely pre-dates the start of routine her-2
testing in the UK. It is notable that development ofspecific molecular predictive markers for RT has lagged
behind that of predictive markers for modern, targeted,
systemic therapies, for which the therapeutic target it-
self, or molecules associated with it, have often proved
good candidate markers. Recently the search for RT pre-
dictive markers has followed an analogous course, focus-
sing mainly on proteins involved with DNA metabolism
and repair, since DNA is the target of RT. Some poten-
tial markers have been identified [5,21,22] but none have
yet entered clinical practice. In addition, The mechanism
by which PSMD9, or the 26S proteasome generally, is
associated with RT response remains unclear although
emerging evidence suggests that the proteasome may
be an upstream regulator of some of key DNA repair
pathways [23], with low proteasome activity reducing
DNA repair capacity and causing relative RT sensitivity.
In particular, efficient proteasome function is poten-
tially required for homologous recombination, a path-
way for repairing RT-induced DNA damage, and for
post-replication repair [23], providing a mechanistic
framework to support the emerging use of proteasome in-
hibitors as radio-sensitizers [24,25]. The 26S proteasome
inhibitor, Bortezomib (Velcade; Millenium Pharmaceuti-
cals), has shown a positive clinical benefit for inducing
radio-sensitization in some cancers, yet the majority of
success remains in haematological malignancies and its in-
fluence on solid tumours has been less encouraging [26].
Clinical use of Bortezomib continues to be hampered by
dose-limiting toxicities, drug-resistance and interference
by some natural compounds. Our cell culture work sup-
ports the proposition that the PSMD9 subunit itself repre-
sents a specific and novel target for radio-sensitizing
therapies, since transiently reduced PSMD9 expression at
the time of exposure to RT was associated with reduced
cell survival (Figure 4).
In conclusion, we show that PSMD9 expression may
be a predictive marker for RT in breast cancer. This ob-
servation warrants further prospective evaluation, ideally in
the context of prospective randomized studies of RT, to de-
termine whether PSMD9 expression has clinical utility in
targeting RT to those patients most likely to benefit, or in
selecting patients with relatively RT resistant tumours for
more intensive therapy. We also demonstrate that PSMD9
may itself present a therapeutic target for a further gener-
ation of subunit-specific proteasome inhibitors.
Methods
Ethical issues and study populations
Ethical approval was obtained from Leeds (Central) Re-
search Ethics Committee (reference 08/H1313/49). The
cohort comprised patients treated at the Leeds Teach-
ing Hospital NHS Trust for operable primary breast
cancer between 1993 and 2007 and either having suf-
fered local recurrences (LRs) (n = 32), or having not
Figure 3 Positive expression of PSMD9 is significantly associated with higher rates of local recurrences after RT in breast cancer.
Kaplan–Meier analyses for local recurrence in patient groups with tumours showing positive (any appreciable; “pos”) or negative (no appreciable;
“neg”) staining for PSMD9. A A mixed group of 157 patients. B Patients treated with RT. C Patients not treated with RT.
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free: 52 months), and for whom archival primary resec-
tion blocks and clinical follow up were available. Exten-
sive clinical follow up data, including time from initial
diagnosis to either LR or last follow up, were collected
from patient notes and from Trust computer databases.
LRs were defined as such if they occurred in the same
breast quadrant as the index lesion for conserved
breasts or in association with the mastectomy scar, and
with the same histology (type, grade) and hormone recep-
tor status. Patients were treated with surgery (wide local
excision/mastectomy) with or without adjuvant RT. RT,
when given, was 40 Gy in 15 fractions over 3 weeks. AFigure 4 PSMD9 expression is functionally associated with RT respon
transfected with siRNAs targeting PSMD9 or with non-targeting control. A
Western blotting of MCF7 transfected lysates. B MCF7 cell growth after 48
survival/proliferation assays. C PSMD9 knock-down enhanced the efficacy o
assays. Data points represent means of triplicates (+/- standard deviations).variety of other standard adjuvant therapies were given
(Table 1); these were typically oral anti-hormonal agents
and/or chemotherapy.
Tissue culture, siRNA transfection and MTT assays
Cell lines were obtained from the European Collection of
Animal Cell Cultures and were cultured as described previ-
ously [27,28]. Bimonthly Mycoplasma checks (MycoAlert
Mycoplasma detection assay, Lonza [Basal, Switzerland])
were consistently negative and short tandem repeat profiles
confirmed cell identity. SiRNAs were purchased from
Dharmacon (Waltham, USA) or Ambion (Paisley, UK).
The siRNA against PSMD9 is pool of three independentse in breast cancer cells. Breast cancer cell lines were transiently
PSMD9 was effectively silenced using siRNA, as demonstrated using
h was unaffected by PSMD9 knock-down, as demonstrated using MTT
f RT in breast cancer cell lines, as demonstrated using colony forming
Langlands et al. Molecular Cancer 2014, 13:73 Page 7 of 8
http://www.molecular-cancer.com/content/13/1/73sequences all directed against PSMD9. Cells were reverse
transfected with 50 nM targeting or non-targeting siRNAs
using Lipofectamine RNAiMax (Invitrogen [Paisley, UK]).
MTT (Dimethylthiazol diphenyltetrazolium bromide) as-
says were performed as previously described [29].
Western blot analyses
RIPA lysates (50 mM Tris HCl pH7.4, 150 mM NaCl,
NP40 1%, Complete inhibitors [Roche, Basel, Switzerland])
were prepared from cells and were quantified in triplicate
with RCDC protein assay (BioRad, Hercules, USA).
Western blot analyses were performed as previously
[30] using 25 μg protein per lane on SDS 4–15% poly-
acrylamide gels (Invitrogen, Paisley, UK) and Hybond-
ECL membrane (Amersham Biosciences, Buckinghamshire,
UK). Antibodies and conditions used were mouse anti-
26S proteasome (1:400, 4°C, 16h [Abcam Ab58115,
Cambridge, UK]), mouse anti-actin (1:5000, 20°C, 1 h
[Sigma A1978, Poole, UK]) and goat anti-mouse HRP-
conjugated secondary (1:1000, 20°C, 1 h [Santa-Cruz
Biotech sc-2005, Santa Cruz, USA]). Proteins were visua-
lised with Super Signal West Femto Substrate (Thermo
Scientific, USA) and a ChemiDoc Gel Documentation Sys-
tem using Quantity One software (version 4.6.1) (Bio-Rad,
Hercules, CA, UK).
Immunohistochemistry, pathology scoring, and statistics
Tissue microarrays (TMAs) were constructed using
0.6mm cores selected from the most representative
tumour areas (determined by analysis of H&E stained sec-
tions by breast pathologists ETV, RAM-S and AMH) of
formalin-fixed paraffin-embedded (FFPE) archival resec-
tion tissue blocks of primary tumours. 3 separate cores
were taken from different areas of each tumour. Liver and
kidney tissues were also placed within TMAs to allow
orientation, to act as internal controls, and to assess equal
staining across slides. TMAs were sectioned onto Super-
Frost Plus slides (Menzel-Glaser, Braunschweig,
Germany). Sections were dewaxed with xylene and
rehydrated through graded ethanol before blocking of
endogenous peroxidase activity in 3% H2O2 (10 min).
Epitopes were retrieved by heating in a pressure-cooker
in 1% vector antigen unmasking solution (2 min) and
non-specific binding blocked using 10% Casein solution
(20 min). Slides were incubated with mouse anti-26S
proteasome (Ab58115, Abcam, Cambridge, UK) at a di-
lution of 1:300 for 16 h at 4°C. Staining was visualised
using Envision kits (Dako, Gostrup, Denmark). Slides
were washed in tris-buffered saline and stained in cop-
per sulphate, Harris’s haematoxylin and finally in Scotts
substitute for 1 min before dehydration. Slides were
mounted in DPX (Fluka, UK). Stained sections were
digitally scanned using Scanscope XT (Aperio) at 40x
magnification and were observed using ImageScope(Aperio). Staining of tissues was scored for immunoreac-
tivity by two independent observers (FEL and RAM-S)
taking into account intensity and percentage of positively
stained tumour cells using the Allred system [17]. Staining
intensity scores (0, no staining; 1, weak; 2, moderate; 3,
strong) were added to percentage positivity scores (0, 0%;
1, <1%; 2, 1-5%; 3, 6–25%; 4, 26–75%; 5 > 75%) giving to-
tals of 0 or 2–8. When scores given by individuals differed
substantially consensus scores were determined by con-
sultation with a further independent consultant breast
pathologist (AMH). Statistical analyses were performed
using SPSS v16.0 with tests (two tailed) as described in the
text. P values of less than 0.05 were considered to indicate
significance.
Colony-forming assays
These were performed essentially as described previ-
ously [9]. Cell lines were transfected in T25 cm2 tissue
culture flasks and cultured for 48 h as normal. Irradi-
ation was then performed using a 320 System Irradiator
(320 kV x-ray source; NDT Equipment Suppliers, UK).
Cells were irradiated with single fractions of 0, 2, 4, 6, 8
and 10 Gy and cultured as normal for a further 4 h.
Each flask of cells was then seeded into triplicate 10 cm
tissue culture plates. Cells were seeded at different
densities according to cell type and radiation exposure
in order to achieve an assessable number of colonies.
The cells were then cultured undisturbed for 14 days.
Cells were fixed and stained in 5 mg/ml Crystal violet,
50% Methanol, 20% Ethanol (20°C, 20 s) before being
rinsed in water twice. Colonies were then counted
using Quantity One 1-D analysis Software (BioRad) ver-
sion 4.6. Calculation of survival fractions (SF) was per-
formed using the equation: SF = colonies counted/cells
plated × (PE/100), where PE is a measure of individual
plating efficiency.
Additional files
Additional file 1: Table S1. PSMD9 expression does not correlate with
clinico-pathological features of the breast cancer cohort (n = 157).
Additional file 2: Figure S1. Receiver Operator Curve analysis was used
to select a cut-off to dichotomise PSMD9 expression.
Additional file 3: Table S2. Lymph node (LN) status and surgery type,
but not other clinico-pathological features, differ significantly between
breast cancer patients treated with (+) and without (-) radiotherapy.
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